David A Santos insider trades: Rigel Pharmaceuticals (RIGL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | RIGL | ↓ Sell | 3,921 | $21.38 | $84K | Direct | Feb 6, 2025 (1d) |
| Feb 5, 2024 | RIGL | ↓ Sell | 14,519 | $1.14 | $16K | Direct | Feb 6, 2024 (1d) |
| Feb 2, 2023 | RIGL | ↓ Sell | 5,388 | $1.66 | $9K | Direct | Feb 6, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RIGL insiders
Open-market trades in the last 12 months
About David A Santos's insider trades
David A Santos is EVP, Chief Commercial Officer at Rigel Pharmaceuticals (RIGL). Since Feb 2, 2023, David has reported no open-market purchases and 3 sales worth $109K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RIGL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.